ArticleHereditas2026
OGT-mediated O-GlcNAcylation of MAGI1 exacerbates high glucose-triggered inflammation and dedifferentiation of vascular smooth muscle cells by activating the PI3K/AKT pathway.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundVasculopathy is a vital complication of diabetes mellitus (DM), and the dysfunction of vascular smooth muscle cells (VSMCs) is a central event in its pathogenesis. O-GlcNAc transferase (OGT), the enzyme catalyzing O-GlcNAcylation, is implicated in diabetic complications, yet its specific role in VSMC dysfunction remains poorly defined. This study aimed to elucidate the function of OGT and its downstream signaling in high glucose (HG)-induced VSMC injury.
methodsA cellular model of DM was established by treating human VSMCs with HG. Expression analysis was performed by RT-qPCR and western blot, respectively. Cell viability, proliferation, and migration/invasion were assessed using CCK-8, EdU, and transwell assays. Inflammatory cytokine secretion was measured by ELISA. A diabetic mouse model was established by streptozotocin (STZ) to validate the in vivo relevance.
resultsMembrane-associated guanylate kinase with an inverted domain structure-1 (MAGI1) was up-regulated in DM patients and HG-induced VSMCs. Functionally, MAGI1 knockdown attenuated HG-induced VSMC dysfunction, suppressing proliferation, migration, invasion, inflammatory response, and dedifferentiation. Conversely, MAGI1 overexpression exacerbated these pathological phenotypes. Mechanistically, MAGI1 activated the PI3K/AKT signaling pathway in HG-induced VSMCs. Moreover, OGT mediated the O-GlcNAcylation and stability of MAGI1. Knockdown of OGT alleviated HG-induced VSMC dysfunction and inhibited the PI3K/AKT pathway by reducing MAGI1 expression. In vivo, OGT deficiency ameliorated kidney injury and systemic inflammation in STZ-induced diabetic mice.
conclusionThis study demonstrates that OGT promotes MAGI1 expression through O-GlcNAc modification to drive VSMC dysfunction. This study not only delineates a previously unrecognized mechanism but also identifies the OGT/MAGI1 axis as a potential therapeutic target for preventing vascular complications in diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.